Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 9, 2024, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The company is a leading global healthcare firm headquartered in Denmark, employing approximately 69,000 people across 80 countries.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It solely reports a specific securities transaction.
| Transaction Detail | Value |
|---|---|
| Instrument | Novo Nordisk ADRs (NVO) |
| Transaction Type | Purchase |
| Volume | 208,385 ADRs |
| Price per ADR | DKK 819.72 |
| Total Value | DKK 170,817.15 |
| Date of Transaction | August 7, 2024 |
| Exchange | New York Stock Exchange |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a single purchase transaction by a board member.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of a transaction by Andreas Helmut Fibig, a Member of the Board of Directors.
Key Facts for Investor Verification
- Board member Andreas Helmut Fibig purchased 208,385 ADRs on August 7, 2024.
- The transaction occurred on the New York Stock Exchange at a price of DKK 819.72 per ADR.
- The total value of the purchase was approximately DKK 170,817.
- This filing does not provide updated financial results or strategic guidance for the company.